Abstract
PDB33 The Associated Costs of Treating Type 2 Diabetes Patients to a Clinically Relevant Composite Endpoint With Liraglutide Versus Exenatide
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
